Immuneering 2026: Revenue ($24.34M), EPS ($0.37) — 10-Q Summary

Immuneering reported a net loss of $24.19M for 2026, up 61.7% from 2025. Revenue was $24.34M, down 62.6% YoY. The company began dosing for MAPKeeper 301, increased enrollment, and plans further trials for atebimetinib combinations. Phase 2 data is expected in 2027.

Original reporting
Published Oct 29, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Immuneering 2026: Revenue ($24.34M), EPS ($0.37) — 10-Q Summary — source image
Decision brief

The 30-second read

$IMRXNeutralMed
01

Why it matters

The filing provides the first public details on trial enrollment acceleration and survival outcomes, which are material for valuation.

02

Market read

New financial loss and trial progress data give traders fresh information to reassess IMRX valuation.

03

What to watch

Potential partnership or licensing deals not disclosed yet could further influence price.

Relevance 8/10Novelty 8/10Timing: post‑market filing

Background

Immuneering Corp filed its Q3 2026 10‑Q, reporting financial results and updates on its atebimetinib combination trials.

Company-level read

Ticker impact

$IMRXNeutralHigh confidence
Context

10-Q filing shows a net loss of $24.19M and Phase 2 trial enrollment ahead of schedule with topline results expected mid‑2028.

Expected impact

potential modest upside on trial progress, but overall bearish pressure from the large loss.

Evidence & confidence

Losses are material for a micro‑cap, yet the trial data is a primary disclosure that can move the share price.

Market effects

Biotech sector may see slight uplift as early‑stage trial data emerges.

US biotech investors likely to react; limited broader market effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The loss may be overstated; focus on upcoming trial data could drive a rebound.

Key entities

  • Immuneering Corp

    Biotech firm developing atebimetinib combinations.

Related articles

$IMRXHigh

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

Immuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N

$IMRXMed

Immuneering presents phase 3 pancreatic cancer trial design

Immuneering Corporation (IMRX) presented its Phase 3 trial design for atebimetinib in pancreatic cancer at the European Society for Medical Oncology Congress. The global study compares atebimetinib with modified chemotherapy against standard treatment, with overall survival as the primary endpoint. The trial follows promising Phase 2a results and is currently recruiting patients.